Rohto Pharmaceutical Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	34,247	42,331	41,518	34,290	27,953
Depreciation & Amortization	17,377	13,143	8,687	7,801	7,673
Loss (Gain) From Sale of Assets	15	175	348	1,338	892
Asset Writedown & Restructuring Costs	43	-	-	-	-
Loss (Gain) From Sale of Investments	892	-1,896	798	285	798
Loss (Gain) on Equity Investments	-92	-166	289	-56	-143
Provision & Write-off of Bad Debts	413	-	-	-	-
Other Operating Activities	2,786	-10,932	-10,218	-6,995	-10,347
Change in Accounts Receivable	-5,184	1,950	-6,787	-7,560	-30
Change in Inventory	-2,069	-4,597	-4,029	-6,105	-3,061
Change in Accounts Payable	-141	-1,288	1,679	1,716	3,323
Change in Other Net Operating Assets	-499	-1,803	1,960	6,210	192
Operating Cash Flow	47,788	36,917	34,245	30,924	27,250
Operating Cash Flow Growth	29.45%	7.80%	10.74%	13.48%	36.20%
Capital Expenditures	-11,494	-9,080	-7,979	-8,473	-10,267
Sale of Property, Plant & Equipment	26	26	272	109	12
Cash Acquisitions	-	-74,479	-	-	-1,203
Sale (Purchase) of Intangibles	-14,757	-1,481	-933	-1,435	-1,061
Investment in Securities	-3,282	-3,563	-7,376	-3,299	-3,652
Other Investing Activities	-60	163	230	178	128
Investing Cash Flow	-29,780	-89,170	-16,317	-13,176	-16,406
Short-Term Debt Issued	2,638	-	656	-	1,273
Long-Term Debt Issued	1,847	40,178	1,605	220	9,450
Total Debt Issued	4,485	40,178	2,261	220	10,723
Short-Term Debt Repaid	-	-2,310	-	-1,341	-
Long-Term Debt Repaid	-7,063	-5,961	-3,484	-8,761	-3,133
Total Debt Repaid	-7,063	-8,271	-3,484	-10,102	-3,133
Net Debt Issued (Repaid)	-2,578	31,907	-1,223	-9,882	7,590
Repurchase of Common Stock	-	-5,000	-	-	-
Common Dividends Paid	-9,264	-7,072	-5,475	-4,676	-3,422
Other Financing Activities	-3	15,484	-7,086	-1,641	-698
Financing Cash Flow	-11,845	35,319	-13,784	-16,199	3,470
Foreign Exchange Rate Adjustments	3,325	3,374	4,703	5,236	4,335
Miscellaneous Cash Flow Adjustments	142	219	23	1	1
Net Cash Flow	9,630	-13,341	8,870	6,786	18,650
Free Cash Flow	36,294	27,837	26,266	22,451	16,983
Free Cash Flow Growth	30.38%	5.98%	16.99%	32.20%	50.47%
Free Cash Flow Margin	10.56%	9.02%	9.70%	9.41%	8.51%
Free Cash Flow Per Share	154.14	121.61	114.80	98.13	74.23
Cash Interest Paid	1,307	888	200	247	228
Cash Income Tax Paid	11,922	11,219	9,970	6,937	8,731
Levered Free Cash Flow	9,061	16,651	15,301	12,450	11,698
Unlevered Free Cash Flow	9,863	17,244	15,423	12,604	11,853
Change in Working Capital	-7,893	-5,738	-7,177	-5,739	424

Source: S&P Global Market Intelligence. Standard template. Financial Sources.